朱雅茜,向宇飞,邓超,周智广

• 1:中南大学湘雅二医院内分泌科 中南大学糖尿病中心

摘要(Abstract)：

<正>1型糖尿病(type 1 diabetes mellitus,T1DM)是一种自身免疫性疾病,遗传易感体在环境等多种因素作用下机体免疫功能出现障碍,自身抗原被激活,活化T、B淋巴细胞和多种其他炎性细胞,这些细胞通过各种细胞因子相互作用,激活多种效应细胞,对胰岛β细胞产生破坏,最终导致糖尿

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81170725);; 欧洲糖尿病研究基金(EFSD/CDS/Lilly-2010);; 教育部长江学者和创新团队发展计划资助(IRT1195)

作者(Author): 朱雅茜,向宇飞,邓超,周智广

参考文献(References)：

• [1]Redon I,Beltrand J,Martin D,et al.Changes in insulin therapy regimens over 10 yr in children and adolescents with type 1diabetes attending diabetes camps[J].Pediatr Diabetes,2013[Epub ahead of print].
• [2]Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group,Tamborlane WV,Beck RW,et al.Continuous glucose monitoring and intensive treatment of type1 diabetes[J].N Engl J Med,2008,359(14):1464-1476.
• [3]Bergenstal RM,Tamborlane WV,Ahmann A,et al.Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes[J].N Engl J Med,2010,363(4):311-320.
• [4]Purnell JQ,Zinman B,Brunzell JD,et al.The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type1 diabetes mellitus:results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study(DCCT/EDIC)study[J].Circulation,2013,127(2):180-187.
• [5]Ludvigsson J,Faresjo M,Hjorth M,et al.GAD treatment and insulin secretion in recent-onset type 1 diabetes[J].N Engl J Med,2008,359(18):1909-1920.
• [6]Ludvigsson J,Krisky D,Casas R,et al.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus[J].N Engl J Med,2012,366(5):433-442.
• [7]Sherry N,Hagopian W,Ludvigsson J,et al.Teplizumab for treatment of type 1 diabetes(Protege study):1-year results from a randomised,placebo-controlled trial[J].Lancet,2011,378(9790):487-497.
• [8]Hagopian W,Ferry RJ,Sherry N,et al.Teplizumab preserves C-Peptide in recent-onset type 1 diabetes:two-year results from the randomized,placebo-controlled protege trial[J].Diabetes,2013,62(11):3901-3908.
• [9]Herold KC,Gitelman SE,Ehlers MR,et al.Teplizumab(AntiCD3 mAb)Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial:Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders[J].Diabetes,2013,62(11):3766-3774.
• [10]Pescovitz MD,Greenbaum CJ,Krause-Steinrauf H,et al.Rituximab,B-lymphocyte depletion,and preservation of betacell function[J].N Engl J Med,2009,361(22):2143-2152.
• [11]Pescovitz MD,Greenbaum CJ,Bundy B,et al.B-Lymphocyte Depletion with Rituximab and Beta-Cell Function:Two-Year Results[J].Diabetes Care,2013[Epub ahead of print].
• [12]Orban T,Bundy B,Becker DJ,et al.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes:a randomised,double-blind,placebo-controlled trial[J].Lancet,2011,378(9789):412-419.
• [13]Mastrandrea L,Yu J,Behrens T,et al.Etanercept treatment in children with new-onset type 1 diabetes:pilot randomized,placebo-controlled,double-blind study[J].Diabetes Care,2009,32(7):1244-1249.
• [14]Montes VN,Hirsch IB.Treatment of LADA with etanercept[J].Diabetes Care,2012,35(5):e36.
• [15]Olivieri AN,Iafusco D,Mellos A,et al.Refractory rheumatoid factor positive polyarthritis in an adolescent already suffering from type 1 diabetes mellitus and Hashimoto's thyroiditis successfully treated with Etanercept[J].Ital J Pediatr,2013,39(1):64.
• [16]Moran A,Bundy B,Becker DJ,et al.Interleukin-1 antagonism in type 1 diabetes of recent onset:two multicentre,randomised,double-blind,placebo-controlled trials[J].Lancet,2013,381(9881):1905-1915.
• [17]M Lehrke,N Marx,S Patel,et al.Safety and tolerability of linagliptin in 7400 patients with type 2 diabetes:a pooled comprehensive analysis of prospective safety reporting in placebo-controlled studies[Z].Barcelona:49th EASD Annual Meeting,2013.
• [18]Varanasi A,Bellini N,Rawal D,et al.Liraglutide as additional treatment for type 1 diabetes[J].Eur J Endocrinol,2011,165(1):77-84.
• [19]Araki O,Nakahara R,Ujiie K,et al.Dipeptidyl peptidase-4inhibitors improve glycaemic control in latent autoimmune diabetes in adults(LADA)patients insufficiently controlled despite insulin therapy[Z].Barcelona:49th EASD Annual Meeting,2013.
• [20]Y Hamamoto,S Honjo,Y Kawasaki-Ogita,et al.Long-term effects of liraglutide on pancreatic beta cell function and glycaemic control in type 1 diabetes with residual insulin secretion[Z].Barcelona:49th EASD Annual Meeting,2013.
• [21]Howell JC,Lauf R,Schweitzer JI,et al.Functional Intestinal Incretin Cells Derived From Human Pluripotent Stem Cells[Z].Chicago:American Diabetes Association(ADA)73rd Scientific Sessions,2013.
• [22]P Boyle MB.Diabetes,incretin therapy,pancreatitis and pancreas cancer:meta-analyses[Z].Barcelona:49th EASD Annual Meeting,2013.
• [23]Rezania A,Bruin JE,Riedel MJ,et al.Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice[J].Diabetes,2012,61(8):2016-2029.
• [24]Tuch BE,Hughes TC,Evans MD.Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes[J].Diabetes Metab Res Rev,2011,27(8):928-932.
• [25]Couri CE,Oliveira MC,Stracieri AB,et al.C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus[J].JAMA,2009,301(15):1573-1579.
• [26]Haque R,Lei F,Xiong X,et al.Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity[J].J Immunol,2012,189(3):1228-1236.
• [27]Vanikar AV,Dave SD,Thakkar UG,et al.Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells:a novel therapy for insulindependent diabetes mellitus[J].Stem Cells Int,2010,2010:582382.
• [28]Zhao Y,Jiang Z,Zhao T,et al.Reversal of type 1 diabetes via isletβcell regeneration following immune modulation by cord bloodderived multipotent stem cells[J].BMC Med,2012,10:3.
• [29]Callejas D,Mann CJ,Ayuso E,et al.Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy[J].Diabetes,2013,62(5):1718-1729.
• [30]Alam T,Wai P,Held D,et al.Correction of Diabetic Hyperglycemia and Amelioration of Metabolic Anomalies by Minicircle DNA Mediated Glucose-Dependent Hepatic Insulin Production[J].PLoS One,2013,8(6):e67515.
• [31]Barton FB,Rickels MR,Alejandro R,et al.Improvement in outcomes of clinical islet transplantation:1999-2010[J].Diabetes Care,2012,35(7):1436-1445.